Drug Profile
Valrubicin
Alternative Names: AD 32; N-Trifluoroacetyladriamycin-14-valerate; NSC 246131; Valstar; ValtaxinLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Anthra Pharmaceuticals
- Developer Endo Pharmaceuticals Solutions
- Class Anthracyclines; Antineoplastics; Cytostatics; Small molecules
- Mechanism of Action DNA repair enzyme inhibitors; Reactive oxygen species stimulants; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Bladder cancer
- Discontinued Endometrial cancer; Ovarian cancer
Most Recent Events
- 24 Jul 2012 CTP alert for NCT01606345 - Endo Pharma is only the collaborator - not added
- 14 Feb 2012 Endo Pharmaceuticals terminates a phase III trial in Bladder cancer in USA (NCT01310803)
- 18 Jul 2011 Endo Pharmaceuticals initiates enrolment in a phase III trial for Bladder cancer in USA (NCT01310803)